BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaedic Society for Sports Medicine (AOSSM) for Tactoset® Injectable Bone Substitute for hardware augmentation. This award highlights the innovative nature of Tactoset, a calcium phosphate based, biocompatible bone graft substitute that incorporates Anika’s core hyaluronic acid (HA) technology, and its use to augment hardware and support bone fragments during surgical procedures. The HA component of Tactoset makes the product highly flowable, easily injectable and able to interdigitate trabecular bone architecture, such as insufficiency fractures, with overall improved handling characteristics compared to competitive products.
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.